Clinical Trial Update: A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON [Phase 3]

View source ↗

Summary

Phase 3 trial of bardoxolone methyl in autosomal dominant polycystic kidney disease was terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Status: TERMINATED | Results posted: 2024-06-11